Supply network capacity planning for semiconductor manufacturing with uncertain demand and correlation in demand considerations

A semiconductor supply network involves many expensive steps, which have to be executed to serve global markets. The complexity of global capacity planning combined with the large capital expenditures to increase factory capacity makes it important to incorporate optimization methodologies for cost reduction and long-term planning. The typical view of a semiconductor supply network consists of layers for wafer fab, sort, assembly, test and demand centers. We present a two-stage stochastic integer-programming formulation to model a semiconductor supply network. The model makes strategic capacity decisions, (i.e., build factories or outsource) while accounting for the uncertainties in demand for multiple products. We use the model not only to analyze how variability in demand affects the make/buy decisions but also to investigate how the correlation between demands of different products affects these strategic decisions. Finally, we demonstrate the value of incorporating demand uncertainty into a decision-making scheme.     

Determinants and Relationships in Sectoral Trade: A Bilateral Model for Knitwear Clothing

The generalized aggregated trade models do not capture the industry or product‐specific competitive situation and overgeneralize the bilateral cases. As a result, product‐specific trade determinants at the sectoral or bilateral level cannot be sufficiently drawn from such generalized models. This holds true for knitwear clothing products, an important component of international textile trade. To remedy this, we propose a sector‐specific bilateral model in the context of knitwear clothing exports from India to the United States. This pair of countries is chosen due to unilateral trade flows as well as to underline the contrasting features of developed north versus developing south. The vector autoregression (VAR) model was found more appropriate than other available modeling choices. We used monthly frequency data from January 2006 to December 2012. The traditional determinants such as exchange rate and price competitiveness remain relevant. Chinese competition emerges as a significant determinant, which underlines the relevance of a sector‐specific bilateral trade model. The 2009 recession showed a clear impact, albeit for only a few months. Our model is parsimonious but has more explanatory power than generalized models. Policy researchers may further explore the model for more fine‐tuned policy on sector‐specific factors. © 2016 Wiley Periodicals, Inc.     

The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans

Introduction: Brodalumab is a new biologic approved by the US Food and Drug Administration in 2017 for the treatment of moderate-severe psoriasis. This study evaluated the impact of the introduction of brodalumab on the pharmacy budget on US commercial health plans.

Methods: An Excel-based health economic decision analytic model with a US health plan perspective was developed. The model incorporated published moderate-to-severe psoriasis prevalence data; market shares of common biologic drugs, including adalimumab, ustekinumab, secukinumab, ixekizumab, and etanercept, used for the treatment of moderate–severe psoriasis; 2017-year Wholesale Acquisition Costs for the biologic drugs; drug dispensing fee; patient co-pay; and drug contracting discount. Total annual health plan costs for the biologic drugs were estimated. Scenarios with different proportions of patients treated with brodalumab were compared to a control scenario when no brodalumab was used.

Results: In a hypothetical commercial health plan covering two million members, 7,038 moderate-to-severe psoriasis patients were estimated to be eligible for treatment with brodalumab. Prior to brodalumab approval, the proportions of patients treated by other biologics were estimated at 50.8% for adalimumab, 13.5% for ustekinumab, 14.1% for secukinumab, 4.4% for ixekizumab, and 17.2% for etanercept. With a 20% drug price discount applied to all biologics, the annual health plan costs for brodalumab, adalimumab, ustekinumab, secukinumab, ixekizumab, and etanercept were estimated at $37,224, $49,166, $55,084, $56,061, $64,396, and $57,170, respectively. When no brodalumab is used, the total annual pharmacy budget for the biologics used among these patients was estimated at $414,362,647. Among scenarios where the proportions of brodalumab usage were 3%, 8%, 16%, and 30%, the total annual pharmacy cost was estimated to be reduced by $3,698,129, $9,861,677, $19,723,355, and $36,981,290, respectively.

Conclusion: Based on the economic model, brodalumab has the potential to substantially reduce pharmacy expenditures for the treatment of patients with moderate-to-severe plaque psoriasis in the US.     

Linking resources to career satisfaction through work–family enrichment

Using the work–family enrichment (WFE) model and social exchange theory as the theoretical underpinnings, our study investigates WFE as a mediator of the effects of material resources (i.e. salary, job security) as well as psychological resources (i.e. self-esteem) on career satisfaction. Our study gathered data from frontline employees (FLEs) in small- and medium-sized hotels in Delhi, the capital city of India, and gauged the aforementioned relationships through partial least squares structural equation modelling. The results suggest that FLEs’ satisfaction with salary and job security needs fosters WFE that in turn gives rise to satisfaction with their career in the organisation. The results also suggest that FLEs’ satisfaction with esteem needs stimulates WFE that in turn engenders career satisfaction. We discuss theoretical and practical implications of the empirical findings in the paper.     

Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting

Objective: To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (SUs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 inhibitors (DPP-4i), all combined with metformin.

Methods: A short-term decision-analytic model with a 1-year time horizon was developed from a payer’s perspective in the United States setting. Costs and benefits associated with four clinical end-points (glycated hemoglobin [A1C], body weight, systolic blood pressure [SBP], and risk of hypoglycemia) were evaluated in the analysis. The impact of DAPA and other glucose-lowering therapy classes on these clinical end-points was estimated from a network meta-analysis (NMA). Data for costs and quality-adjusted life-years (QALYs) associated with a per-unit change in these clinical end-points were taken from published literature. Drug prices were taken from an annual wholesale price list. All costs were inflation-adjusted to December 2016 costs using the medical care component of the consumer price index. Total costs (both medical and drug costs), total QALYs, and incremental cost-effectiveness ratios (ICERs) were estimated. Sensitivity analyses (SA) were performed to explore uncertainty in the inputs. To assess face validity, results from the short-term model were compared with long-term models published for these drugs.

Results: The total annual medical cost for DAPA was less than that for GLP-1RA ($186 less), DPP-4i ($1,142 less), SU ($2,474 less), and TZD ($1,640 less). Treatment with DAPA resulted in an average QALY gain of 0.0107, 0.0587, 0.1137, and 0.0715 per treated patient when compared with GLP-1RA, DPP-4i, SU, and TZD, respectively. ICERs for DAPA vs SU and TZD were $19,005 and $25,835, respectively. DAPA was a cost-saving option when compared with GLP-1RAs and DPP-4is. Among all four clinical end-points, change in weight had the greatest impact on total annual costs and ICERS. Sensitivity analysis showed that results were robust, and results from the short-term model were found to be similar to those of published long-term models.

Conclusion: This analysis showed that DAPA was cost-saving compared with GLP-1RA and DPP-4i, and cost-effective compared with SU and TZD in the US setting over 1 year. Furthermore, the results suggest that, among the four composite clinical end-points, change in weight and SBP had an impact on cost-effectiveness results.     

Mobile technologies for police tasks: An Australian study

Mobile technologies are increasingly adopted by information intensive organizations such as public police corporations to support the tasks of its employees, for information management and innovation. However, because police organizations are government organizations, technology decisions are largely made by managers and politicians with budget being a key factor. Therefore, whether the technologies adopted are suitable for police tasks, and if they enhance performance, is generally not assessed. The aim of this research is to establish if mobile technologies support police tasks, and if Tablet PCs especially are suitable for specialist police tasks of the Criminal Investigators and Sexual Offence and Child Abuse Units. Guided by an interpretive paradigm and the theory of task technology fit, this research explores the use of Tablet PCs by the two police units for improved performance. Because information is critical for police tasks, data collected via focus groups establishes the impact of these technologies on case investigations, information management, and the performance of these units with the use of Tablet PCs. The contribution this study makes to mobile information systems is that if technology dimensions are suitable for information based tasks, the outcome is virtualization of processes through which improved performance is achieved due to reduced costs, transparency, teamwork, and quick and informed decisions. The findings of this research can be used by police organizations, as well as by other organizations, for effective implementation of mobile technologies.     

Is India Specialising in Polluting Industries? Evidence from US‐India Bilateral Trade

Recently, the apex environmental agency of India observed that domestic industrial pollution has been increasing at an alarming rate over the last two decades, and the need to rein in traditional polluting industries. This raises the pertinent question of whether the poor domestic pollution regime has affected the pattern of India's trade in dirty manufactured products in the post‐liberalisation era since 1991. We find that on the whole, India has remained a net importer of pollution‐intensive manufactured goods; however, there is a distinct trend of increasing specialisation in specific dirty industries especially in the bilateral trade with high‐income countries, and to a lesser degree with low‐income countries. The USA being India's single largest country trading partner in the post‐liberalisation era, we test for pollution offshoring at the finer industry level in US‐India bilateral trade. While we find that the pollution haven effect is not significant, India's specialisation in certain dirty manufacturing industries through the last decade remains a disturbing trend. India needs to integrate environmental sustainability within industrial growth urgently, and it is pertinent to implement policies which would reflect the true pollution costs in an industry that is increasingly competing in the international market.     

Development of Scale to Measure Objectives-Oriented Investment Behavior

Abstract

While planning for personal finances, researchers recommend investors adapting systematically planned investment behaviors that align investments with their financial objectives; however, they fail to provide a scale for the measurement of such behaviors. Therefore, this study develops a scale, conducts exploratory and confirmatory factor analysis, and provides evidence of the reliability of the scale measuring objectives-oriented investment behaviors. Examining a cross-sectional data of 448 investors collected through the new scale, the study finds that a majority of the investors’ do not follow objectives-oriented behavior. The results inform that the selection of investment avenues and allocation of funds were not aligned with investors’ financial objectives.